Day: January 19, 2021

MONTREAL, Jan. 19, 2021 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce the closing of its previously-announced bought-deal public offering (the “Offering”) pursuant to which the Company issued 16,727,900 units of the Company (the “Units”) at a price of US$2.75 per Unit (equivalent to approximately C$3.51 per Unit) (the “Offering Price”) for aggregate gross proceeds to the Company of US$46,001,725 (equivalent to approximately C$58,714,929), including the full exercise of the over-allotment option to purchase an additional 2,181,900 Units at the Offering Price.Each Unit is comprised of one common share of the Company (a “Common Share”) and one-half...

Stellantis: Building a world leader in sustainable mobilityA new company with the agility, creativity and efficiency to capture the opportunities of the new era of mobility, offering innovative solutions that will help change the way society movesRich heritage stemming from storied and iconic automotive marques, innovative mobility brands and deep roots in the communities in which it operatesWell positioned to compete in global markets with 39 electrified vehicles available by the end of 2021Significant scale with well-established commercial positions in Europe, North America and Latin AmericaStrong opening balance sheetTargeting more than €5 billion of annual steady state synergiesRobust governance structure from Day One dedicated to creating superior value for all stakeholdersUnwavering commitment of the 400,000 employees to exceed...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATESMONTREAL, Jan. 19, 2021 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce the closing of its previously-announced bought-deal public offering (the “Offering”) pursuant to which the Company issued 16,727,900 units of the Company (the “Units”) at a price of US$2.75 per Unit (equivalent to approximately C$3.51 per Unit) (the “Offering Price”) for aggregate gross proceeds to the Company of US$46,001,725 (equivalent to approximately C$58,714,929), including the full exercise of the over-allotment option to purchase an additional 2,181,900 Units at the Offering Price.The Offering...

NE PAS DISTRIBUER À DES AGENCES DE TRANSMISSION AMÉRICAINES NI DIFFUSER AUX ÉTATS-UNISMONTRÉAL, 19 janv. 2021 (GLOBE NEWSWIRE) — Theratechnologies Inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX) ), société biopharmaceutique dont les activités sont axées sur le développement et la commercialisation de traitements innovateurs, est heureuse d’annoncer qu’elle a complété son placement par voie de prise ferme annoncé préalablement (le « placement ») aux termes duquel la Société a émis 16 727 900 unités de la Société (les « unités ») à un prix de 2,75 $ US par unité (soit l’équivalent d’environ 3,51 $ C par unité) (le « prix du placement »), pour un produit brut totalisant 46 001 725 $ US (soit l’équivalent d’environ 58 714 929 $ C) à un prix). Le placement comprend l’exercice intégral de l’option de surallocation...

TORONTO, Jan. 19, 2021 (GLOBE NEWSWIRE) — E2Gold Inc. (TSXV: ETU) (the “Company” or “E2Gold”) is pleased to report that it has completed a large helicopter-borne magnetic survey on its Hawkins gold project in northern Ontario.The detailed magnetic survey, which collected 1,139 km of data, was conducted by Scott Hogg and Associates. It covers the area around the McKinnon Zone, a shallow, 3.5 km long, Inferred Mineral Resource of 328,800 ounces of gold (6.2 million tonnes grading 1.65 g/t gold)i, and is providing E2Gold geologists and geophysicists with added data and a strong base for drill hole planning.Eric Owens, President and CEO, said, ”It is a top-quality survey, and yields a level of detail previously unattained. The results will form a basis for all future work and interpretations. We have a crew onsite now preparing for...

ATCHISON, Kan., Jan. 19, 2021 (GLOBE NEWSWIRE) — Matt Greeno has been promoted to the newly created position of Lead Master Distiller at MGP Ingredients, Inc., (Nasdaq: MGPI) a leading supplier of premium distilled spirits and specialty wheat proteins. He is charged with ensuring distillation quality and supporting new product development for contract distilling customers and MGP Brands.Greeno will guide the company’s Master Distillers and process engineers and oversee technical processes across MGP distillery operations in Atchison, Kansas, Lawrenceburg, Indiana, and Washington, D.C. On the product development side, he will collaborate with MGP’s alcohol R&D and Innovations team to develop new product concepts and custom mash bills and distillates.“Matt’s new role supports our strategy of developing ‘bench strength’ with MGP...

EAST SETAUKET, NY, Jan. 19, 2021 (GLOBE NEWSWIRE) — Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, today announced an agreement on a Phase 1b clinical trial with City of Hope, a world-renowned independent cancer research and treatment center. The trial will assess the combination of Lixte’s first-in-class protein phosphatase inhibitor LB-100 with a standard regimen for untreated, extensive stage-disease small cell lung cancer (ED-SCLC).LB-100 will be given in combination with carboplatin, etoposide and atezolizumab, an FDA approved but marginally effective regimen, in previously untreated ED-SCLC. The dose of LB-100 will be escalated with fixed doses of the 3-drug regimen to reach a recommended Phase 2 dose (RP2D)....

TORONTO, Jan. 19, 2021 (GLOBE NEWSWIRE) — Inventus Mining Corp. (TSX VENTURE: IVS) (“Inventus” or the “Company”) is pleased to announce assay results from its first drill hole WL-20-01 and details about its second drill hole WL-21-02, part of an ongoing 3,000-metre drill program at its 100%-owned Wolf Lake and Cobalt Hill properties near Sudbury, Ontario.A total of 556 metres of drilling has been completed to date with a minimum of 7 additional holes planned at the Wolf Lake and Cobalt Hill targets. The initial drill program is designed to properly sample the polymetallic gold mineralization and test the mineralized structures at depth.Drill hole WL-20-01 was vertical and designed to test the near surface mineralization, it intersected:The first hole has validated the presence of polymetallic mineralization with individual core...

-Enhanced Signaling Pathways Show Increased Potency Through Expression of MicroRNAs--Publication Further Supports Capricor’s Exosome Platform Advancement-LOS ANGELES, Jan. 19, 2021 (GLOBE NEWSWIRE) — Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class cell- and exosome-based therapeutics for the treatment and prevention of a variety of diseases and disorders, announced today the publication, in collaboration with researchers at Cedars-Sinai Medical Center, which demonstrates the utility of pathway-enhancing culture conditions and small molecule inhibitors to retain markers of cell therapy potency. The publication titled, “Small molecule inhibitors and culture conditions enhance therapeutic cell and EV potency via activation...

SUNNY ISLES, Fla., Jan. 19, 2021 (GLOBE NEWSWIRE) — Bespoke Extracts, Inc. (OTC Pink: BSPK), producer of high quality, hemp-derived CBD products, today announced that it has entered into an amendment with the holders of the Company’s original issue discount convertible debentures with an original issuance date of December 24, 2019 and subsequently amended on May 28, 2020, August 21, 2020 and December 10, 2020, in the aggregate outstanding principal amount of $500,000. Pursuant to the latest amendment (No. 4), the conversion price of the debentures was increased from $0.001 to $0.05 per share, subject to adjustment for stock splits, stock dividends and similar transactions.Danny Pollack, Chief Executive Officer of Bespoke Extracts, stated, “This latest amendment, providing for an increase in the conversion price of our discount convertible...